Halstead Michael insider trades
Halstead Michael has filed 24 Form 4s with the SEC that we hold, for ITCI (President) and Helus Pharma Inc. (CYBN) (Chief Executive Officer). Across all of them we count 1 purchase worth $1.3M and 42 sales worth $27.3M reported on Form 4. In the last 12 months: 1 purchase ($1.3M) and 0 sales ($0). The largest single trade was a sale of 104,775 shares of ITCI worth $5.0M, dated 2021-12-21. The first filing on our record is dated 2021-12-23 and the latest 2026-09-21.
ITCI
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-12-21 | S, sale reported on Form 4 | 36,434 | $1.7M | 2021-12-23 |
| 2021-12-21 | S, sale reported on Form 4 | 104,775 | $5.0M | 2021-12-23 |
| 2021-12-21 | S, sale reported on Form 4 | 22,620 | $1.1M | 2021-12-23 |
| 2021-12-21 | S, sale reported on Form 4 | 8,690 | $397.5K | 2021-12-23 |
| 2021-12-21 | S, sale reported on Form 4 | 4,344 | $194.9K | 2021-12-23 |
| 2022-01-10 | S, sale reported on Form 4 | 2,504 | $104.5K | 2022-01-11 |
| 2022-01-10 | S, sale reported on Form 4 | 12,755 | $520.5K | 2022-01-11 |
| 2022-01-10 | S, sale reported on Form 4 | 4,380 | $175.7K | 2022-01-11 |
| 2022-02-22 | S, sale reported on Form 4 | 6,589 | $366.9K | 2022-02-23 |
| 2022-02-22 | S, sale reported on Form 4 | 4,550 | $250.2K | 2022-02-23 |
| 2022-02-24 | S, sale reported on Form 4 | 3,718 | $194.7K | 2022-02-25 |
| 2022-02-24 | S, sale reported on Form 4 | 4,188 | $216.2K | 2022-02-25 |
| 2022-12-01 | S, sale reported on Form 4 | 27,204 | $1.5M | 2022-12-02 |
| 2022-12-01 | S, sale reported on Form 4 | 22,796 | $1.2M | 2022-12-02 |
| 2023-02-21 | S, sale reported on Form 4 | 100 | $5.0K | 2023-02-22 |
| 2023-02-21 | S, sale reported on Form 4 | 643 | $30.4K | 2023-02-22 |
| 2023-02-21 | S, sale reported on Form 4 | 9,296 | $432.8K | 2023-02-22 |
| 2023-02-21 | S, sale reported on Form 4 | 1,100 | $53.5K | 2023-02-22 |
| 2023-02-24 | S, sale reported on Form 4 | 7,906 | $371.8K | 2023-02-27 |
| 2023-03-10 | S, sale reported on Form 4 | 2,500 | $106.3K | 2023-03-13 |
| 2023-03-10 | S, sale reported on Form 4 | 14,208 | $613.8K | 2023-03-13 |
| 2023-03-13 | S, sale reported on Form 4 | 6,868 | $309.0K | 2023-03-13 |
| 2023-03-13 | S, sale reported on Form 4 | 476 | $21.0K | 2023-03-13 |
| 2023-11-13 | S, sale reported on Form 4 | 41,067 | $2.2M | 2023-11-14 |
| 2023-11-13 | S, sale reported on Form 4 | 8,933 | $476.8K | 2023-11-14 |
| 2024-01-11 | S, sale reported on Form 4 | 30,360 | $2.0M | 2024-01-12 |
| 2024-01-11 | S, sale reported on Form 4 | 1,486 | $100.8K | 2024-01-12 |
| 2024-01-11 | S, sale reported on Form 4 | 18,154 | $1.2M | 2024-01-12 |
| 2024-02-02 | S, sale reported on Form 4 | 11,146 | $739.8K | 2024-02-05 |
| 2024-02-02 | S, sale reported on Form 4 | 714 | $48.0K | 2024-02-05 |
| 2024-02-26 | S, sale reported on Form 4 | 7,215 | $501.7K | 2024-02-27 |
| 2024-02-26 | S, sale reported on Form 4 | 392 | $27.5K | 2024-02-27 |
| 2024-02-26 | S, sale reported on Form 4 | 300 | $20.6K | 2024-02-27 |
| 2024-03-07 | S, sale reported on Form 4 | 12,912 | $854.0K | 2024-03-11 |
| 2024-03-07 | S, sale reported on Form 4 | 220 | $14.7K | 2024-03-11 |
| 2024-03-11 | S, sale reported on Form 4 | 6,107 | $402.0K | 2024-03-11 |
| 2024-03-11 | S, sale reported on Form 4 | 1,238 | $82.6K | 2024-03-11 |
| 2024-11-12 | S, sale reported on Form 4 | 15,105 | $1.3M | 2024-11-14 |
| 2024-11-12 | S, sale reported on Form 4 | 1,648 | $149.8K | 2024-11-14 |
| 2024-11-12 | S, sale reported on Form 4 | 6,116 | $548.2K | 2024-11-14 |
| 2024-11-13 | S, sale reported on Form 4 | 5,343 | $475.1K | 2024-11-14 |
| 2024-11-13 | S, sale reported on Form 4 | 13,371 | $1.2M | 2024-11-14 |
Helus Pharma Inc. (CYBN)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-09-21 | P, purchase reported on Form 4 | 100,000 | $1.3M | 2026-09-21 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1521548) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms